187 related articles for article (PubMed ID: 36128875)
21. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
[TBL] [Abstract][Full Text] [Related]
23. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Nezu M; Suzuki N; Yamamoto M
Am J Nephrol; 2017; 45(6):473-483. PubMed ID: 28502971
[TBL] [Abstract][Full Text] [Related]
24. Nrf2-Keap1 pathway-mediated effects of resveratrol on oxidative stress and apoptosis in hydrogen peroxide-treated rheumatoid arthritis fibroblast-like synoviocytes.
Zhang Y; Wang G; Wang T; Cao W; Zhang L; Chen X
Ann N Y Acad Sci; 2019 Dec; 1457(1):166-178. PubMed ID: 31475364
[TBL] [Abstract][Full Text] [Related]
25. Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding Mode.
Georgakopoulos N; Talapatra S; Dikovskaya D; Dayalan Naidu S; Higgins M; Gatliff J; Ayhan A; Nikoloudaki R; Schaap M; Valko K; Javid F; Dinkova-Kostova AT; Kozielski F; Wells G
J Med Chem; 2022 May; 65(10):7380-7398. PubMed ID: 35549469
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of miR-200a protects cardiomyocytes against hypoxia-induced apoptosis by modulating the kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 signaling axis.
Sun X; Zuo H; Liu C; Yang Y
Int J Mol Med; 2016 Oct; 38(4):1303-11. PubMed ID: 27573160
[TBL] [Abstract][Full Text] [Related]
27. Dihydrokaempferol (DHK) ameliorates severe acute pancreatitis (SAP) via Keap1/Nrf2 pathway.
Liang X; Hu C; Liu C; Yu K; Zhang J; Jia Y
Life Sci; 2020 Nov; 261():118340. PubMed ID: 32860805
[TBL] [Abstract][Full Text] [Related]
28. Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model.
Kim S; Indu Viswanath AN; Park JH; Lee HE; Park AY; Choi JW; Kim HJ; Londhe AM; Jang BK; Lee J; Hwang H; Lim SM; Pae AN; Park KD
Neuropharmacology; 2020 May; 167():107989. PubMed ID: 32032607
[TBL] [Abstract][Full Text] [Related]
29. Emerging Screening Approaches in the Development of Nrf2-Keap1 Protein-Protein Interaction Inhibitors.
Leung CH; Zhang JT; Yang GJ; Liu H; Han QB; Ma DL
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31509940
[TBL] [Abstract][Full Text] [Related]
30. The Keap1/Nrf2 protein axis plays a role in osteoclast differentiation by regulating intracellular reactive oxygen species signaling.
Kanzaki H; Shinohara F; Kajiya M; Kodama T
J Biol Chem; 2013 Aug; 288(32):23009-20. PubMed ID: 23801334
[TBL] [Abstract][Full Text] [Related]
31. Neutrophil elastase inhibitor suppresses oxidative stress in obese asthmatic rats by activating Keap1/Nrf2 signaling pathway.
Zheng JQ; Zhang GR; Li J; Bi HW
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):361-369. PubMed ID: 30657578
[TBL] [Abstract][Full Text] [Related]
32. Caffeic acid prevents acetaminophen-induced liver injury by activating the Keap1-Nrf2 antioxidative defense system.
Pang C; Zheng Z; Shi L; Sheng Y; Wei H; Wang Z; Ji L
Free Radic Biol Med; 2016 Feb; 91():236-46. PubMed ID: 26721592
[TBL] [Abstract][Full Text] [Related]
33. Caffeoylquinic acids isolated from Lonicera japonica Thunb. as TAK1 inhibitors protects against LPS plus IFN-γ-stimulated inflammation by interacting with KEAP1-regulated NRF2 activation.
Ge L; Jiang Y; Li Y; Xie Q; Miao Y; Wu Z; Zeng X
Biomed Pharmacother; 2023 Sep; 165():115038. PubMed ID: 37418981
[TBL] [Abstract][Full Text] [Related]
34. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
[TBL] [Abstract][Full Text] [Related]
35. Activation of KEAP1/NRF2 stress signaling involved in the molecular basis of hemin-induced cytotoxicity in human pro-erythroid K562 cells.
Georgiou-Siafis SK; Tsiftsoglou AS
Biochem Pharmacol; 2020 May; 175():113900. PubMed ID: 32156661
[TBL] [Abstract][Full Text] [Related]
36. NF-κB and Keap1 Interaction Represses Nrf2-Mediated Antioxidant Response in Rabbit Hemorrhagic Disease Virus Infection.
Hu B; Wei H; Song Y; Chen M; Fan Z; Qiu R; Zhu W; Xu W; Wang F
J Virol; 2020 May; 94(10):. PubMed ID: 32161178
[TBL] [Abstract][Full Text] [Related]
37. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
38. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
39. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.
Habib E; Linher-Melville K; Lin HX; Singh G
Redox Biol; 2015 Aug; 5():33-42. PubMed ID: 25827424
[TBL] [Abstract][Full Text] [Related]
40. Recent progress and applications of small molecule inhibitors of Keap1-Nrf2 axis for neurodegenerative diseases.
Wang J; Cao Y; Lu Y; Zhu H; Zhang J; Che J; Zhuang R; Shao J
Eur J Med Chem; 2024 Jan; 264():115998. PubMed ID: 38043492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]